Acute effect of whey peptides upon blood pressure of hypertensive rats, and relationship with their angiotensin-converting enzyme inhibitory activity
Article first published online: 7 DEC 2011
© 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Molecular Nutrition & Food Research
Special Issue: Carotenoids in Nutrition and Health - Developments and Future Trends
Volume 56, Issue 2, pages 316–324, February 2012
How to Cite
Tavares, T., Sevilla, M.-Á., Montero, M.-J., Carrón, R. and Malcata, F. X. (2012), Acute effect of whey peptides upon blood pressure of hypertensive rats, and relationship with their angiotensin-converting enzyme inhibitory activity. Mol. Nutr. Food Res., 56: 316–324. doi: 10.1002/mnfr.201100381
- Issue published online: 14 MAR 2012
- Article first published online: 7 DEC 2011
- Manuscript Accepted: 15 SEP 2011
- Manuscript Revised: 5 SEP 2011
- Manuscript Received: 7 JUN 2011
- Fundação para a Ciência e a Tecnologia – Portugal. Grant Number: SFRH/BD/31604/2006
- Angiotensin-converting enzyme;
- Antihypertensive effects;
- Bioactive peptides;
- Spontaneously hypertensive rats;
- Whey proteins
Scope: The aim of this study was to investigate the antihypertensive effect of a peptide fraction (PepC) obtained from a whey protein concentrate following hydrolysis by Cynara cardunculus, as well as of its fraction with MW below 3 kDa (PepCF). Both these concentrates encompassed peptides that exhibited potent in vitro inhibition of angiotensin-converting enzyme (ACE): two were released from α-lactalbumin – KGYGGVSLPEW and DKVGINYW, and one from β-lactoglobulin – DAQSAPLRVY.
Methods and results: Upon oral administration, by gastric intubation, of 400 mg/kg body weight (bw) of those peptide concentrates, or 5 mg/kg bw of the corresponding synthetic peptides, to 12 wk-old spontaneously hypertensive rats (SHR), the systolic and diastolic blood pressures were monitored by the tail-cuff method – before, and 2, 4, 6, 8 and 24 h afterwards. Water and zofenopril (5 mg/kg bw) – a known ACE-inhibitor, were used as negative and positive controls, respectively. Acute administration of PepC, PepCF, KGYGGVSLPEW, DKVGINYW and DAQSAPLRVY caused antihypertensive effects in SHR; the maximum effect occurred by 4 h and 6 h after administration of the peptide concentrates and the synthetic peptides, respectively. PepC and KGYGGVSLPEW also showed ACE-inhibitory activity in vivo: the pressor effect of angiotensin I was significantly lower, and the response to bradykinin increased when the rats were pre-treated with either product.
Conclusion: Our results strongly suggest that PepC will be effective as nutraceutical ingredient for the formulation of functional foods aimed at hypertension control.